IR Biosciences Holdings Inc. (IRBS) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist IR Biosciences Holdings Inc. (IRBS) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026IR Biosciences Holdings Inc. (IRBS) Gesundheitswesen & Pipeline-Uebersicht
IR BioSciences Holdings, Inc., a development stage biotechnology firm, focuses on researching and developing therapies for pulmonary fibrosis, influenza, and radiation-induced Neutropenia. Their pipeline includes Homspera, Radilex, and Viprovex, targeting stem cell stimulation and immune system modulation, operating within the competitive healthcare sector.
Investmentthese
IR BioSciences Holdings, Inc. presents a high-risk, high-reward investment opportunity typical of development-stage biotechnology companies. The company's value hinges on the successful development and commercialization of its pipeline, particularly Homspera, Radilex, and Viprovex. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. The company's small market capitalization and limited resources amplify both the potential upside and downside. The company's beta of 5.01 indicates high volatility. Upcoming catalysts include progress updates on clinical trials and potential collaborations with larger pharmaceutical firms. The primary risk lies in the uncertainty of drug development, regulatory hurdles, and the company's ability to secure additional funding. Investors should carefully consider the speculative nature of this investment and the potential for significant losses.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- IR BioSciences Holdings, Inc. operates as a development stage biotechnology company.
- The company focuses on therapies for pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia.
- Key compounds include Homspera, Radilex, and Viprovex, targeting stem cell stimulation and immune system enhancement.
- The company was founded in 1999 and is headquartered in Scottsdale, Arizona.
- The company has a market capitalization of $0.00B and a beta of 5.01.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary compounds with potential therapeutic applications.
- Focus on unmet medical needs in specific disease areas.
- Experienced management team with scientific expertise.
- Potential for strategic partnerships and collaborations.
Schwaechen
- Development stage company with limited financial resources.
- Dependence on successful clinical trial outcomes.
- High regulatory hurdles and approval risks.
- Small team size.
Katalysatoren
- Upcoming: Clinical trial results for Homspera in pulmonary fibrosis.
- Upcoming: Potential partnerships with pharmaceutical companies for drug development.
- Upcoming: Regulatory submissions for Radilex and Viprovex.
- Ongoing: Research and development efforts to expand the therapeutic pipeline.
- Ongoing: Efforts to secure additional funding and investment.
Risiken
- Potential: Failure to secure regulatory approvals for its therapies.
- Potential: Unsuccessful clinical trial outcomes.
- Potential: Competition from larger pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: High volatility associated with development stage biotechnology companies.
Wachstumschancen
- Expansion into New Therapeutic Areas: IR BioSciences has the opportunity to leverage its existing technology and expertise to expand into new therapeutic areas beyond its current focus. This could involve developing therapies for other respiratory diseases, autoimmune disorders, or oncology indications. The market for these therapies is substantial, with global pharmaceutical sales exceeding billions of dollars annually. Success in this area would require significant investment in research and development and strategic partnerships with other biotechnology companies or academic institutions.
- Strategic Partnerships and Collaborations: IR BioSciences can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline. These partnerships can provide access to funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations with smaller biotechnology companies to replenish their pipelines. Successful partnerships can significantly enhance IR BioSciences' value and increase its chances of bringing its therapies to market.
- Advancement of Clinical Trials: IR BioSciences' growth is heavily dependent on the successful advancement of its clinical trials for Homspera, Radilex, and Viprovex. Positive clinical trial results would validate the efficacy and safety of these compounds and increase their commercial potential. The clinical trial process is lengthy and expensive, but it is essential for obtaining regulatory approval and bringing new therapies to market. The company's ability to effectively manage its clinical trials and generate positive data will be critical to its success.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA is a critical milestone for IR BioSciences. Regulatory approval allows the company to commercialize its therapies and generate revenue. The regulatory approval process is rigorous and requires extensive data on the safety and efficacy of the therapies. The company's ability to navigate the regulatory landscape and secure approvals will be essential to its long-term success.
- Intellectual Property Protection: IR BioSciences can strengthen its competitive position by securing and maintaining strong intellectual property protection for its technologies and therapies. Patents provide exclusive rights to commercialize these innovations and prevent competitors from entering the market. The biotechnology industry is highly competitive, and intellectual property protection is essential for maintaining a competitive advantage. The company's ability to effectively manage its patent portfolio will be critical to its long-term success.
Chancen
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of clinical trials and regulatory approvals.
- Growing market for therapies targeting pulmonary fibrosis, influenza, and radiation-induced Neutropenia.
Risiken
- Competition from larger pharmaceutical companies.
- Failure to secure regulatory approvals.
- Unsuccessful clinical trial outcomes.
- Inability to secure additional funding.
Wettbewerbsvorteile
- Proprietary compounds and technologies (Homspera, Radilex, Viprovex).
- Intellectual property protection through patents.
- Expertise in stem cell stimulation and immune system modulation.
- Potential first-mover advantage in specific therapeutic areas.
Ueber IRBS
Founded in 1999 and headquartered in Scottsdale, Arizona, IR BioSciences Holdings, Inc. is a development stage biotechnology company operating through its subsidiary, ImmuneRegen BioSciences, Inc. The company is dedicated to the research and development of innovative therapies primarily focused on addressing unmet medical needs in areas such as pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. Their core focus revolves around the development of Homspera, along with its derivatives Radilex and Viprovex. These compounds are being explored for their potential in human stem cell stimulation, immune system stimulation, anti-infective activity, vaccine adjuvancy, and wound healing. As a development stage company, IR BioSciences is currently in the pre-revenue phase, heavily investing in research and clinical trials to advance its pipeline. The company's strategy involves rigorous scientific investigation and preclinical studies to validate the efficacy and safety of its therapeutic candidates. The company aims to partner with larger pharmaceutical companies or pursue regulatory approval independently to bring its therapies to market. The company's small size and limited resources present both challenges and opportunities as it navigates the complex and competitive biotechnology landscape.
Was das Unternehmen tut
- Researches and develops therapies for pulmonary fibrosis.
- Develops treatments for influenza infection.
- Creates therapies for radiation-induced Neutropenia.
- Develops Homspera for human stem cell stimulation.
- Develops Radilex for immune system stimulation.
- Develops Viprovex for anti-infective activity.
- Explores vaccine adjuvancy applications.
- Investigates wound healing applications.
Geschaeftsmodell
- Focuses on research and development of novel therapies.
- Aims to license or partner its technologies with larger pharmaceutical companies.
- Seeks regulatory approval for its therapies to commercialize them.
- Generates revenue through licensing agreements, partnerships, and potential future product sales.
Branchenkontext
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. Companies like IR BioSciences operate in a landscape dominated by larger pharmaceutical firms with extensive resources. The market for therapies targeting pulmonary fibrosis, influenza, and radiation-induced Neutropenia is substantial, driven by aging populations and increasing prevalence of these conditions. Success in this industry requires significant investment in research and development, strategic partnerships, and a robust intellectual property portfolio. The biotechnology sector is subject to stringent regulatory oversight by agencies such as the FDA.
Wichtige Kunden
- Future patients suffering from pulmonary fibrosis.
- Future patients suffering from influenza infection.
- Future patients suffering from radiation-induced Neutropenia.
- Potential pharmaceutical partners seeking innovative therapies.
- Healthcare providers prescribing the company's therapies.
Finanzdaten
Chart & Info
IR Biosciences Holdings Inc. (IRBS) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer IRBS verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer IRBS.
Kursziele
Wall-Street-Kurszielanalyse fuer IRBS.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von IRBS auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Chet Leach D.A.B.T.
CEO
Chet Leach D.A.B.T. serves as the Chief Executive Officer of IR BioSciences Holdings, Inc. His background includes expertise in toxicology and pharmacology, holding the designation of Diplomate of the American Board of Toxicology (D.A.B.T.). He has experience in guiding early-stage companies through the complexities of the biotechnology industry, including navigating regulatory pathways and securing funding. His scientific background is expected to be crucial for guiding the company's research and development efforts.
Erfolgsbilanz: As CEO, Chet Leach is responsible for overseeing the strategic direction and operations of IR BioSciences. Given the company's development stage, his key achievements likely involve securing funding for research and development, advancing the company's pipeline through preclinical and clinical studies, and establishing strategic partnerships. His leadership is focused on advancing the development of Homspera, Radilex, and Viprovex and bringing them to market.
IRBS OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that IR BioSciences Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB) or major exchanges like NYSE or NASDAQ. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and potential for illiquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation.
- Potential for delisting or trading suspension.
- Limited liquidity and wider bid-ask spreads.
- Greater price volatility.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or investigations.
- Company has been in operation since 1999.
- Focus on research and development in biotechnology.
- Development of specific therapeutic compounds (Homspera, Radilex, Viprovex).
- CEO with relevant scientific background (Chet Leach D.A.B.T.).
Haeufige Fragen zu IRBS
What are the key factors to evaluate for IRBS?
IR Biosciences Holdings Inc. (IRBS) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary compounds with potential therapeutic applications.. Primary risk to monitor: Potential: Failure to secure regulatory approvals for its therapies.. This is not financial advice.
How frequently does IRBS data refresh on this page?
IRBS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IRBS's recent stock price performance?
Recent price movement in IR Biosciences Holdings Inc. (IRBS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary compounds with potential therapeutic applications.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IRBS overvalued or undervalued right now?
Determining whether IR Biosciences Holdings Inc. (IRBS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IRBS?
Before investing in IR Biosciences Holdings Inc. (IRBS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IRBS to a portfolio?
Potential reasons to consider IR Biosciences Holdings Inc. (IRBS) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary compounds with potential therapeutic applications.. Additionally: Focus on unmet medical needs in specific disease areas.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of IRBS?
Yes, most major brokerages offer fractional shares of IR Biosciences Holdings Inc. (IRBS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track IRBS's earnings and financial reports?
IR Biosciences Holdings Inc. (IRBS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for IRBS earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to the company's OTC listing and development stage.